News from Oxford BioTherapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 13, 2017, 03:00 ET Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate based therapies,...


Feb 09, 2017, 03:00 ET Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans

Oxford BioTherapeutics ("OBT"), an international biotechnology company developing clinical stage antibody therapeutics for cancer, today announced...


Jan 14, 2015, 09:05 ET Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to an Oncology Target

Oxford BioTherapeutics announces today that Boehringer Ingelheim has exercised an option to receive exclusive rights to an oncology target from an...


Nov 25, 2014, 06:00 ET $1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics Initiates First-in-Human Study of Enhanced Antibody for Treatment of Acute Myeloid Leukemia

Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announce today that they have...


Oct 02, 2014, 06:48 ET Oxford BioTherapeutics and Berlin-Chemie/Menarini Group Progress Antibody-Drug Conjugate as Second Clinical Development Candidate in $1 Billion Oncology Investment Alliance

Oxford BioTherapeutics (OBT) and Berlin Chemie/Menarini Group announce today that they have designated a novel antibody-drug conjugate (ADC)...


Jul 08, 2014, 05:00 ET Oxford BioTherapeutics Appoints Dr Eugen Leo as Head of Clinical Development

Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the...


May 07, 2014, 04:00 ET Oxford BioTherapeutics Takes Exclusive Rights to Use Amgen Xenomouse® Antibodies and ImmunoGen Technology to Develop Novel Antibody-Drug Conjugate for HER2-Negative Breast Cancer

Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the...


Jan 15, 2014, 09:00 ET Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors

Oxford BioTherapeutics, an international biotechnology company developing antibody-drug conjugates for cancer, today announced the appointment of...


Dec 09, 2013, 07:11 ET Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia as First Clinical Development Candidate in $1 Billion Oncology Investment Alliance

Oxford BioTherapeutics (OBT) and Berlin-Chemie (Menarini Group) announce today that they have designated a novel enhanced antibody targeting acute...


Jun 26, 2013, 07:07 ET Oxford BioTherapeutics Appoints Bryan G. Morton as Chairman

Oxford BioTherapeutics (OBT), a global biotechnology company developing first-in-class, antibody-based cancer medicines to fulfil unmet patient...


Apr 29, 2013, 04:00 ET Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer

Oxford BioTherapeutics (OBT) and Boehringer Ingelheim (BI) today announce a new alliance focused on the discovery of novel cancer antibody...


May 02, 2012, 05:58 ET Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland

Oxford BioTherapeutics (OBT) today announces the appointment of Dr Esteban Pombo-Villar as Chief Operations Officer (COO) of the OBT group. In...


Jan 11, 2012, 11:18 ET Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director

Oxford BioTherapeutics (OBT) today announces that it has appointed C. Glenn Begley as a senior clinical advisor and non-executive director....


Apr 06, 2011, 06:00 ET Oxford BioTherapeutics Licenses BioWa's POTELLIGENT(R) Technology for the Research and Development of its Therapeutic Antibodies in Cancer

BioWa, Inc. (BioWa) and Oxford BioTherapeutics Ltd (OBT) today announced that they have entered into a license agreement to provide OBT with access...